Rchr
J-GLOBAL ID:201801013860719919   Update date: Jan. 30, 2024

Yokoyama Satoru

Yokoyama Satoru
Affiliation and department:
Research field  (1): Tumor biology
Research keywords  (2): がん遺伝子 ,  腫瘍生物学
Research theme for competitive and other funds  (8):
  • 2022 - 2025 Cancer pathophysiology and treatment from the perspective of dual-mode control of EGFR
  • 2019 - 2022 Alternative activation mechanisms of receptor tyrosine kinases in inflammation-induced cancer progression
  • 2018 - 2021 悪性黒色腫におけるがん遺伝子とがん抑制遺伝子からみる表現型の差異
  • 2015 - 2018 Identification of Scientific evidence for Traditional Kampo theory by gene expression analysis
  • 2016 - 2018 悪性黒色腫の新規治療法を目指した転写因子SOX10の機能解析
Show all
Papers (65):
  • Sisca Ucche, Satoru Yokoyama, Marija Mojic, Kohei Oki, Chikako Ohshima, Haruka Tsuihiji, Ichiro Takasaki, Hideaki Tahara, Yoshihiro Hayakawa. GSTA4 governs melanoma immune resistance and metastasis. Molecular cancer research : MCR. 2022
  • Jun-Ichiro Takahashi, Shiori Nakamura, Iimi Onuma, Yue Zhou, Satoru Yokoyama, Hiroaki Sakurai. Synchronous intracellular delivery of EGFR-targeted antibody-drug conjugates by p38-mediated non-canonical endocytosis. Scientific reports. 2022. 12. 1. 11561-11561
  • Keisuke Yonehara, Yue Zhou, Jun-Ichiro Takahashi, Satoru Yokoyama, Kei Tomihara, Makoto Noguchi, Hiroaki Sakurai. RSK-Mediated Non-canonical Activation of EphA2 by Tamoxifen. Biological & pharmaceutical bulletin. 2022. 45. 2. 162-168
  • Satoru Yokoyama, Atsushi Takahashi, Ryota Kikuchi, Soshi Nishibu, Jennifer A Lo, Miroslav Hejna, Wooyoung M Moon, Shinichiro Kato, Yue Zhou, F Stephen Hodi, et al. SOX10 Regulates Melanoma Immunogenicity through an IRF4-IRF1 Axis. Cancer research. 2021. 81. 24. 6131-6141
  • Amira A Abdellatef, Yue Zhou, Akane Yamada, Sahar A Elmekkawy, Aki Kohyama, Satoru Yokoyama, Meselhy R Meselhy, Yuji Matsuya, Hiroaki Sakurai, Yoshihiro Hayakawa. Synthetic E-guggulsterone derivative GSD-1 inhibits NF-κB signaling and suppresses the metastatic potential of breast cancer cells. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2021. 140. 111737-111737
more...
MISC (4):
Professional career (1):
  • 博士(医) (東北大学)
Work history (4):
  • 2019/01 - 現在 University of Toyama
  • 2011/04 - 2018/12 University of Toyama Institute of Natural Medicine
  • 2008/08 - 2011/03 Cutaneous Biology Research Center Research Fellow
  • 2006/07 - 2008/07 Dana-Farber Cancer Institute Research Fellow
Association Membership(s) (4):
THE MOLECULAR BIOLOGY SOCIETY OF JAPAN ,  日本がん転移学会 ,  THE JAPANESE ASSOCIATION FOR MOLECULAR TARGET THERAPY OF CANCER ,  THE JAPANESE CANCER ASSOCIATION
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page